Oriane Marmontel

Dr. Oriane Marmontel

Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
OMOriane Marmontel
Oriane Marmontel
PRPierre Antoine Rollat‐Farnier
Pierre Antoine Rollat‐Farnier
AWAnne-Sophie WOZNY
Anne-Sophie WOZNY
SCSybil Charrière
Sybil Charrière
XVXavier Vanhoye
Xavier Vanhoye
MFMathilde Di Filippo
Mathilde Di Filippo

11 January 2016 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
CCCyrielle Caussy
Cyrielle Caussy
SCSybil Charrière
Sybil Charrière
Aline MeirhaegheAline Meirhaeghe
Aline Meirhaeghe
JDJean Dallongeville
Jean Dallongeville
ELEtienne Lefai
Etienne Lefai
CMChristophe Marçais
Christophe Marçais

1 January 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ARAntoine Rimbert
Antoine Rimbert
XVXavier Vanhoye
Xavier Vanhoye
DCDramane Coulibaly
Dramane Coulibaly
MMMarie Marrec
Marie Marrec
MPMatthieu Pichelin
Matthieu Pichelin
MDMathilde Di-Filippo
Mathilde Di-Filippo
Objective: Primary hypobetalipoproteinemia is characterized by LDL-C (low-density lipoprotein cholesterol) concentrations below the fifth percentile. Primary hypobetalipoproteinemia mostly results from heterozygous mutations in the APOB (apolipoprotein B) and PCSK9 genes, and a polygenic origin is hypothesized in the remaining cases. Hypobetalipoproteinemia patients present an increased risk of nonalcoholic fatty liver disease and steatohepatitis. Here, we compared hepatic alterations between monogenic, polygenic, and primary hypobetalipoproteinemia of unknown cause. Approach and Results: Targeted next-generation sequencing was performed in a cohort of 111 patients with hypobetalipoproteinemia to assess monogenic and polygenic origins using an LDL-C-dedicated polygenic risk score. Forty patients (36%) had monogenic hypobetalipoproteinemia, 38 (34%) had polygenic hypobetalipoproteinemia, and 33 subjects (30%) had hypobetalipoproteinemia from an unknown cause. Patients with monogenic hypobetalipoproteinemia had lower LDL-C and apolipoprotein B plasma levels compared with those with polygenic hypobetalipoproteinemia. Liver function was assessed by hepatic ultrasonography and liver enzymes levels. Fifty-nine percent of patients with primary hypobetalipoproteinemia presented with liver steatosis, whereas 21% had increased alanine aminotransferase suggestive of liver injury. Monogenic hypobetalipoproteinemia was also associated with an increased prevalence of liver steatosis (81% versus 29%, P <0.001) and liver injury (47% versus 0%) compared with polygenic hypobetalipoproteinemia. Conclusions: This study highlights the importance of genetic diagnosis in the clinical care of primary hypobetalipoproteinemia patients. It shows for the first time that a polygenic origin of hypobetalipoproteinemia is associated with a lower risk of liver steatosis and liver injury versus monogenic hypobetalipoproteinemia. Thus, polygenic risk score is a useful tool to establish a more personalized follow-up of primary hypobetalipoproteinemia patients.

23 March 2018 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
OMOriane Marmontel
Oriane Marmontel
SCS. Charrière
S. Charrière
TST. Simonet
T. Simonet
VBV. Bonnet
V. Bonnet
SDS. Dumont
S. Dumont
MFM. Di Filippo
M. Di Filippo

Verified
Journal Article
Open access
PDF file
YKYara Abou Khalil
Yara Abou Khalil
OMOriane Marmontel
Oriane Marmontel
JFJean Ferrières
Jean Ferrières
FPFrançois Paillard
François Paillard
CYCécile Yelnik
Cécile Yelnik
MVMathilde Varret
Mathilde Varret
Primary hypercholesterolemia is characterized by elevated LDL-cholesterol (LDL-C) levels isolated in autosomal dominant hypercholesterolemia (ADH) or associated with elevated triglyceride levels in familial combined hyperlipidemia (FCHL). Rare APOE variants are known in ADH and FCHL. We explored the APOE molecular spectrum in a French ADH/FCHL cohort of 5743 unrelated probands. The sequencing of LDLR, PCSK9, APOB, and APOE revealed 76 carriers of a rare APOE variant, with no mutation in LDLR, PCSK9, or APOB. Among the 31 APOE variants identified here, 15 are described in ADH, 10 in FCHL, and 6 in both probands. Five were previously reported with dyslipidemia and 26 are novel, including 12 missense, 5 synonymous, 2 intronic, and 7 variants in regulatory regions. Sixteen variants were predicted as pathogenic or likely pathogenic, and their carriers had significantly lower polygenic risk scores (wPRS) than carriers of predicted benign variants. We observed no correlation between LDL-C levels and wPRS, suggesting a major effect of APOE variants. Carriers of p.Leu167del were associated with a severe phenotype. The analysis of 11 probands suggests that carriers of an APOE variant respond better to statins than carriers of a LDLR mutation. Altogether, we show that the APOE variants account for a significant contribution to ADH and FCHL.

1 December 2020 in Atherosclerosis
Verified
Journal Article
Closed access
CDCharlotte Decourt
Charlotte Decourt
AJAlexandre Janin
Alexandre Janin
MMMarine Moindrot
Marine Moindrot
NCNicolas Chatron
Nicolas Chatron
SNSéverine Nony
Séverine Nony
MDMathilde Di-Filippo
Mathilde Di-Filippo